GNS 396Alternative Names: GNS396
Latest Information Update: 08 Jul 2016
At a glance
- Originator Genoscience
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 08 Jul 2016 Preclinical trials in Acute myeloid leukaemia in France (unspecified route)